Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer.

[1]  S. Lightman,et al.  Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer , 2004, Clinical & Experimental Metastasis.

[2]  M. Housset,et al.  Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer , 2004, Cancer Chemotherapy and Pharmacology.

[3]  P. Abrahamsson.  Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.

[4]  K. Akakura.  [Serum chromogranin A in prostate cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[5]  S. Chevalier,et al.  Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate , 2002, The Prostate.

[6]  A. Bjartell,et al.  Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. , 2002, Urologic oncology.

[7]  T. H. van der Kwast,et al.  Different profiles of neuroendocrine cell differentiation evolve in the PC‐310 human prostate cancer model during long‐term androgen deprivation , 2002, The Prostate.

[8]  D. Bostwick,et al.  Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin , 2001, The Prostate.

[9]  M. Motta,et al.  Somatostatin up-regulates topoisomerase II alpha expression and affects LNCaP cell cycle , 2001, Molecular and Cellular Endocrinology.

[10]  J. Laissue,et al.  Erratum to: Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.

[11]  L. Dogliotti,et al.  Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin‐A, prostate‐specific antigen, and insulin‐like growth factor‐1 in advanced prostate cancer patients , 2001, The Prostate.

[12]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Abrahamsson,et al.  Neuroendocrine pathogenesis in adenocarcinoma of the prostate. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Cappia,et al.  Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  L. Dogliotti,et al.  Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Montironi,et al.  Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.

[17]  D. Bostwick,et al.  High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  L. Dogliotti,et al.  Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.

[19]  J. Overgaard,et al.  Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  H. Klocker,et al.  Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. , 2000, The Journal of urology.

[21]  J. Hugosson,et al.  Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment , 2000, The Prostate.

[22]  T. Kwast,et al.  Androgen Deprivation of the Prohormone Convertase-310 Human Prostate Cancer Model System Induces Neuroendocrine Differentiation , 2000 .

[23]  P. Dasgupta,et al.  Lipophilization of somatostatin analog RC‐160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro , 2000, British journal of pharmacology.

[24]  R. Grobholz,et al.  Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. , 2000, Pathology, research and practice.

[25]  A. Shabsigh,et al.  Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. , 1999, The Journal of urology.

[26]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[27]  E. Caporossi,et al.  [Serum chromogranin A in prostate cancer. Preliminary results]. , 1999, Minerva medica.

[28]  E. Seregni,et al.  The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. , 1999, Anticancer research.

[29]  A. Schally,et al.  Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. , 1999, Cancer research.

[30]  T. H. van der Kwast,et al.  Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. , 1999, The American journal of pathology.

[31]  M. Motta,et al.  Somatostatin and the phosphorylation of the epidermal growth factor/transforming growth factor α (TGFα) receptor in LNCaP cells: interactions with a locally produced TGFα , 1998 .

[32]  L. Deftos,et al.  Granins and prostate cancer. , 1998, Urology.

[33]  A. Bjartell,et al.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.

[34]  G. Pruneri,et al.  Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy , 1998, The Prostate.

[35]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: An update , 1998 .

[36]  H. Bonkhoff.  Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status , 1998, The Prostate. Supplement.

[37]  M. Astill,et al.  Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients , 1998, Journal of clinical laboratory analysis.

[38]  H. Frierson,et al.  Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.

[39]  M. Salvatore,et al.  Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. , 1997, The Journal of clinical endocrinology and metabolism.

[40]  T. H. van der Kwast,et al.  The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.

[41]  C. Olsson,et al.  Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. , 1997, Urologic oncology.

[42]  M. Stridsberg,et al.  Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? , 1997, The Prostate.

[43]  T. H. van der Kwast,et al.  Neuroendocrine differentiation in human prostatic tumor models. , 1996, The American journal of pathology.

[44]  R. Jian,et al.  Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. , 1996, Gut.

[45]  P. di Sant'Agnese,et al.  Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.

[46]  O. Cussenot,et al.  Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. , 1996, The Journal of urology.

[47]  S. Lamberts,et al.  Drug therapy : octreotide , 1996 .

[48]  V. Mazzaferro,et al.  The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. , 1996, Digestion.

[49]  S. Nilsson,et al.  Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. , 1995, Cancer research.

[50]  G. Millot,et al.  Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog , 1995, Molecular and Cellular Endocrinology.

[51]  J. Reubi,et al.  Somatostatin receptors in human prostate and prostate cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[52]  S. Lamberts,et al.  Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. , 1995, Biochemical pharmacology.

[53]  O. Sartor,et al.  A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone‐refractory prostate cancer , 1995, Cancer.

[54]  F. Algaba,et al.  Neuroendocrine cells in peripheral prostatic zone: age, prostatic intraepithelial neoplasia and latent cancer-related changes. , 1995, European urology.

[55]  D. Bostwick,et al.  Neuroendocrine Differentiation in Prostatic Intraepithelial Neoplasia and Adenocarcinoma , 1994, The American journal of surgical pathology.

[56]  C. Logothetis,et al.  SMS 201-995 in the treatment of refractory prostatic carcinoma. , 1994, Anticancer research.

[57]  P. di Sant'Agnese,et al.  Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. , 1993, Urology.

[58]  R. Bianchi,et al.  Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. , 1993, The Journal of clinical endocrinology and metabolism.

[59]  C. Logothetis,et al.  Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. , 1993, The Journal of urology.

[60]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma , 1992 .

[61]  E. Krenning,et al.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.

[62]  P. Scardino,et al.  Elevated plasma chromogranin-A concentrations in prostatic carcinoma. , 1991, The Journal of urology.

[63]  A. Bogdén,et al.  Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. , 1990, Cancer research.

[64]  L. Grimelius,et al.  The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". , 1989, Pathology, research and practice.

[65]  A. Schally.  Oncological applications of somatostatin analogues. , 1988, Cancer research.

[66]  M. Rudin,et al.  Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). , 1988, Cancer research.

[67]  A. Schally,et al.  Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers. , 1988, Progress in clinical and biological research.

[68]  D. Coy,et al.  Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. , 1987, Life sciences.

[69]  F. V. Defeudis,et al.  Pharmacological studies of somatostatin and somatostatin-analogues: therapeutic advances and perspectives. , 1987, Life sciences.

[70]  S. Salmon.  Advances in oncology. , 1983, The Western journal of medicine.